ISOFOL — Isofol Medical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK198.74m
- SEK88.00m
Brief: Isofol Presents Conclusions From The In-Depth Analysis Of The Agent Study
Brief: Isofol's BOD Appoints Roger Tell As Acting CEO
Brief: Isofol Medical Says CEO Resigns At His Own Request
Brief: Isofol Medical Q1 EPS at SEK -0.09
Brief: Isofol Initiates Preclinical Evaluation Of Arfolitixorin With Oncosyne AS
Brief: Isofols Appoints Roy Jonebrant As New CFO
Brief: Isofol's Board Appoints Thomas Andersson As New CEO Of The Company
Brief: Isofol Medical Proposes No Dividend For 2022
Brief: Isofol Medical Q4 EPS at SEK -0.16
Brief: Isofol Obtains Request To Call For EGM
Brief: Isofol To Call EGM To Decide On Liquidation
Brief: Isofol Medical CFO And Deputy CEO Gustaf Albèrt To Step Down During 2023
Brief: CEO Ulf Jungnelius To Leave Isofol Medical On June 1, 2023
Brief: Isofol Says Agent Study Confirms Topline Results
Brief: Isofol Q3 Loss SEK 32.5 Mln
Brief: Isofol Reports Data From Agent Study
Brief: Isofol Says Having Received Access To Additional Data, Co Does Not Consider It Justified To Continue Conducting AGENT Study
Brief: Isofol Medical Q2 Loss For Period Widens To SEK 54.0 Million
Brief: Isofol Announces Topline Results Of Phase III Agent Study